skip to main content

Pheochromocytoma — RCPSC IM MCQ

Instant feedback + full explanation. One question, done properly.

HardEndocrinologyPheochromocytomaRCPSC IM

A 33-year-old woman has a first estrogen-associated proximal DVT. The estrogen has been stopped, she has completed three months of anticoagulation and bleeding risk is low. What should determine whether treatment continues?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Individualize duration using recurrence risk, bleeding risk and preference

The best answer is “Individualize duration using recurrence risk, bleeding risk and preference”. After adequate acute treatment, estrogen-associated VTE requires individualized discussion of recurrence and bleeding risk. Neither universal lifelong treatment nor automatic stopping without shared review is appropriate; thrombophilia testing rarely dictates duration by itself, and residual venous obstruction should not be used as the sole endpoint.

Reference: Thrombosis Canada, venous thromboembolism duration of treatment: https://thrombosiscanada.ca/hcp/practice/clinical_guides?guideID=DURATIONOFANTICOAGULANTTHERAPY&language=en-ca